Becton Dickinson & Co. (BDX) Falls 4.5% for January 04

Equities Staff |

One of the S&P 500’s big losers for Monday January 04 was Becton Dickinson & Co. (BDX). The company’s stock fell 4.5% to $147.15 on volume of 2.09 million shares.

The stock opened the day at 150.62 and traded between a low of $146.02 and a high of $151.45. The stock finished the day down $6.94 per share. Becton Dickinson & Co. has an average daily volume of 1.03 million and a total float of 210.74 million shares. The 50-day SMA for Becton Dickinson & Co. is $150.06 and its 200-day SMA is $143.00. The high for the stock over the last 52 weeks is $157.50 and the low is $128.87.

Becton Dickinson & Co is a medical technology company, engaged in the manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, general public and clinical laboratories.

Becton Dickinson & Co. is centered in Franklin Lakes, NJ, and has 49,517 employees. Today’s trading day leaves the company with a market cap of $31.01 billionwith a P/E Ratio of 45.3. The company has a P/S ratio of 3.95, P/B ratio of 4.33, and a -4.2.

For a complete fundamental analysis analysis of Becton Dickinson & Co., check out’s Stock Valuation Analysis report for BDX. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Propanc Health Group Corp

Propanc Health Group Corp is an early stage healthcare company. It is engaged in developing new cancer treatments for patients, suffering from pancreatic and colorectal cancer.

Private Markets


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…


Pinterest is a visual discovery and planning tool. Users ("Pinners") use the site and apps to get ideas for their future, such as recipes, places to travel, and products to…